Urose

Quick links to important sections

Urose

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Urose

Understanding Urose

Urose is a pharmacological treatment utilized primarily in the management of lower urinary tract symptoms. It belongs to a class of medications known as alpha-1 adrenoceptor antagonists. These agents are designed to target specific receptors located in the smooth muscle of the prostate and the bladder neck.

Mechanism of Action

The primary function of Urose is to facilitate easier urination by relaxing the muscular tension within the prostate gland and the outlet of the urinary bladder. By binding to alpha-1 receptors, the medication inhibits the signals that cause these muscles to contract. This relaxation reduces the functional obstruction of the urethra, thereby improving the flow of urine and mitigating symptoms such as hesitancy, weak stream, and the sensation of incomplete emptying.

Clinical Applications

Urose is most commonly indicated for the treatment of the signs and symptoms associated with Benign Prostatic Hyperplasia (BPH), a non-cancerous enlargement of the prostate gland. While BPH is a common condition associated with aging, it can significantly affect quality of life by disrupting normal urinary patterns.

It is important to note that while Urose addresses the symptoms of prostate enlargement by relaxing muscle tissue, it does not physically shrink the size of the prostate itself. It is often used as a long-term management strategy to maintain urinary function and comfort.

What side effects are possible with Urose?

Possible side effects and safety information

The safety profile of Urose (Ursodiol) is formally documented by regulatory agencies, with adverse reactions classified primarily within the Gastrointestinal and Hepatobiliary Disorders system-organ classes. The frequency of reported events is categorized based on data from clinical trials and post-marketing surveillance.


Adverse Reactions by Frequency

Side effects classified as Common (occurring in up to 10% of patients) often involve the digestive tract and skin. These commonly documented events include diarrhea, abdominal pain or discomfort, pruritus (itching), and rash. Other common reactions include headache and back pain.

Reactions classified as Very Rare (occurring in less than 0.01% of patients) carry significant safety implications. These include the decompensation of hepatic cirrhosis, particularly when used in patients with advanced liver disease, and the calcification of gallstones, which prevents their dissolution. The occurrence of severe right upper abdominal pain is also noted as a very rare adverse reaction.


Safety Constraints and Population Notes

Official regulatory labeling includes specific contraindications that restrict the use of this medicine. Urose must not be used in individuals with conditions that compromise bile flow, such as complete biliary obstruction or acute inflammation of the gallbladder or biliary tract. It is also restricted for use with radio-opaque calcified gallstones.

Specific population safety concerns are documented for women. The medicine is generally contraindicated in pregnancy unless clearly necessary, and pregnancy must be ruled out before treatment initiation. If treatment is required during lactation, breastfeeding must be discontinued. Furthermore, the safety and efficacy of Urose have not been established in the pediatric population.

Overdose and Emergency Response

The official regulatory profile for Urose (Ursodiol) overdose is consistent across major governmental health authorities, reflecting a minimal incidence of severe acute toxicity. Regulatory documents note that no cases of accidental or intentional overdose leading to severe outcomes have been widely reported in official submissions, suggesting a low acute risk.

Documented Overdose Manifestations

According to prescribing information authorized by regulators, the most likely clinical manifestation of a severe overdosage is diarrhea. This single documented symptom indicates that the primary effect of an acute, excessive exposure is generally concentrated within the gastrointestinal system. No other specific severe or life-threatening cardiovascular or neurological outcomes are formally listed in these regulatory summaries.

When to Seek Urgent Medical Help

Urgent medical attention is required for the symptomatic treatment of severe or persistent manifestations, such as diarrhea, if they occur. The officially documented management strategy is to seek immediate medical attention for symptomatic treatment and supportive care. While no specific antidote is mentioned in regulatory documents, procedural steps may include the use of ion-exchange resins. Furthermore, official guidelines may require monitoring liver function tests following an overdose exposure, as specified in government labeling.

Therapeutic Uses of Urose

What Urose treats: main uses and benefits

Urose is commonly used to help with conditions characterized by periods of heightened symptoms in the urological domain. This medicine is applied in addressing the core symptoms related to heightened physiological activity of the bladder. The active ingredient is considered relevant for the treatment of overactive bladder (OAB), a condition presenting with symptoms that interfere with daily functioning.

The core indications involve symptoms related to physical discomfort such as urge urinary incontinence, urgency, and urinary frequency. The active ingredient is considered relevant for the treatment of adults with overactive bladder with these specific symptoms.

The treatment may be part of symptomatic management in clinical settings that involve acute or unstable symptom patterns. The therapy assists with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms by easing the overall symptom burden. It supports general well-being during symptomatic phases. It helps patients cope more steadily with symptom fluctuations. The treatment is considered relevant when short-term symptomatic assistance is needed for these disruptive episodes.


Quick Fact: Supports Management of Urinary Urgency and Frequency

Eligibility and Restrictions for Use

Urose (Ursodiol) eligibility is strictly defined by regulatory bodies for specific patient populations, based on age, physiological status, and co-existing medical conditions.

Approved and Restricted Use

  • Adults are the primary approved population, particularly for Primary Biliary Cholangitis (PBC).
  • Pediatric use (children and adolescents) is generally not established for most uses. However, it may be permitted under restricted use for hepatobiliary disorders associated with Cystic Fibrosis.
  • Older adults are permitted to use the medicine with no required dosage adjustment.

Absolute Contraindications

The medicine must not be used in patients presenting with:

  • Hypersensitivity to ursodiol or any components of the formulation.
  • Complete biliary obstruction (of the common bile duct or cystic duct).
  • Acute inflammation of the gallbladder or biliary tract (e.g., acute cholecystitis).
  • Calcified, radio-opaque gallstones or pigment stones.
  • A non-functioning gallbladder.

Pregnancy and Conditional Use

Use is contraindicated during pregnancy by several major regulatory authorities. Women of childbearing potential are required to use reliable non-hormonal contraception during the course of treatment. Caution is required for use in nursing mothers and in patients with severe chronic liver disease or certain inflammatory gastrointestinal disorders.

What should I know about interactions with other medicines?

Urose (Ursodiol) has officially documented interaction patterns that are defined by regulatory authorities and involve several categories of co-administered medicines.

Interaction Focus Interacting Agents and Official Outcome
Pharmacodynamic Antagonism Estrogens, Oral Contraceptives, and Clofibrate increase cholesterol secretion, which directly counteracts Urose's intended effect on bile composition and may limit its therapeutic action.
Reduced Absorption/Exposure Bile Acid Sequestering Agents (e.g., Cholestyramine) and Aluminum-based Antacids bind to Urose in the gastrointestinal tract, significantly reducing its systemic absorption and efficacy.
Altered Drug Exposure Urose is documented to increase the systemic absorption of ciclosporin, necessitating monitoring and dose adjustment of ciclosporin. Conversely, Urose can reduce the plasma concentrations of certain drugs like nitrendipine and dapsone. Elevated plasma levels of rosuvastatin have also been reported with high-dose co-administration.

To maintain adequate absorption and therapeutic effect, bile acid sequestering agents and aluminum-based antacids must be taken at least 2 hours before or after Urose. Women of childbearing potential receiving Urose for gallstone dissolution are noted to use non-hormonal or low-estrogen contraception due to the antagonistic effect of estrogens.

Mechanism of Action

How Urose Works

Urose (Ursodiol) functions through a multifaceted pharmacodynamic action, primarily focused on modifying bile chemistry and modulating cell survival pathways within the hepatobiliary system.


Modulating Bile Acid Composition and Cholesterol Solubility

This mechanism involves Ursodiol becoming the dominant bile acid within the enterohepatic circulation, competitively displacing hydrophobic, endogenous bile acids. This compositional shift, combined with inhibition of cholesterol secretion and absorption, significantly reduces the cholesterol saturation index of bile. The resulting physiological effect is the micellar solubilization of solid cholesterol, a process that modifies cholesterol crystallization within the bile.


Anti-Apoptotic Action and Cellular Stability

The drug exerts anti-apoptotic action on liver cells (hepatocytes) and bile duct cells (cholangiocytes). Its key interaction involves physically stabilizing the mitochondrial membranes, which inhibits the intrinsic apoptosis cascade, modulating cell fate pathways influenced by accumulated bile acids. This mechanism influences pathways responsible for maintaining hepatocellular and cholangiocyte membrane stability.


Enhancing Biliary Secretion and Flow Dynamics

Ursodiol acts as a modulator to increase bile flow (choleresis) by promoting the function and insertion of key transporters, such as the AE2 exchanger, on the bile duct cells. This upregulation drives the secretion of water and bicarbonate. The resulting physiological effect is an increase in bile volume and flow, facilitating the transport of biliary contents through the system.

Dosage and Administration Information

The administration of Urose (Ursodiol) is structured by explicit, weight-based, and time-dependent instructions. The medicine is provided as oral capsules or tablets and is intended for the oral route of administration. The total daily dose is calculated based on the patient's body weight (milligrams per kilogram per day, mg/kg) and the condition being addressed.

Administration Parameters

Parameter Administration Rule
Dosing Basis Calculated based on patient body weight (mg/kg/day).
Standard Dosing Ranges from 8 to 10 mg/kg/day (gallstone dissolution) to 13 to 15 mg/kg/day (Primary Biliary Cholangitis).
Frequency Pattern Total daily dose is administered in two to four divided portions (divided use).
Timing Constraint The largest or entire dose is often administered at bedtime to optimize bile saturation.
Meal Context Taken with food or meals.
Procedural Constraint Oral formulations are swallowed whole and not crushed.

This structured use defines the necessary consumption context. The duration of therapy ranges from long courses, such as six to twenty-four months for gallstone dissolution (plus three months post-dissolution), to chronic, indefinite use for maintenance in PBC.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Urose

Evidence for Use in Primary Biliary Cholangitis (PBC)

Research into Urose for Primary Biliary Cholangitis (a chronic liver condition formerly known as primary biliary cirrhosis) has been studied for its use in specific cohorts. The core research involved Randomized Controlled Trials (RCTs) where participants were assigned to receive either Urose or a non-active control, alongside extensive observational studies and multicenter registries that tracked patients over many years.

Researchers in these studies primarily focused on measuring changes in biochemical markers of liver health, such as alkaline phosphatase (ALP) and total bilirubin levels. Long-term studies monitored hard endpoints, observing outcomes such as overall survival and the need for a liver transplant.

The findings describe the specific patterns observed in the measured laboratory values for patients using Urose compared to controls. However, certain aspects remain uncertain. While the data indicate patterns of change in the specific lab markers, research exploring the long-term effect on patient-reported outcomes, such as fatigue and pruritus (itching), reported outcomes that varied across studies. Research is ongoing to better understand management strategies for patients who are classified as biochemical non-responders.

Evidence for Use in Cholesterol Gallstone Dissolution

Clinical trials have studied the process of stone dissolution, evaluating adult populations with radiolucent (non-calcified) gallstones. Researchers monitored the extent of dissolution using imaging, categorizing outcomes as complete, partial, or minimal dissolution. Studies reported that populations with smaller stones were observed to have a higher proportion of successful dissolution status in those trials. However, the evidence base is specifically restricted to patients whose gallstones are non-calcified and relatively small. Furthermore, the process of gallstone re-formation after successful dissolution is not fully established by existing research.

Long-Term Evidence and Durability of Study Findings

For PBC, studies have explored outcomes over extended periods, with some observational cohorts tracking patients for over ten years. While the data report sustained patterns in the measured biochemical response, long-term follow-up often relies on observational data collected in registries, and the full extent of durability is not fully established. In contrast, the gallstone prevention and dissolution research scenarios typically involved follow-up durations that were limited to the short-term treatment period.

Frequently Asked Questions (FAQ)

Common questions about Urose (FAQ)


Q: How quickly should I expect Urose to start working?

A: Official information suggests Urose is a medication whose full effects are observed over an extended period. For conditions like dissolving gallstones, clinical studies have noted initial responses involving changes in bile composition may be observed between 3 and 6 months.


Q: How long does the effect of one dose of Urose typically last?

A: Official information from the product's pharmacokinetics shows that the medicine is rapidly absorbed and enters an extensive enterohepatic circulation. This means the active ingredient is continually recycled and eliminated over time, mainly through the feces.


Q: What should I do if I accidentally miss a dose of Urose?

A: Official patient information generally advises that a missed dose should be taken as soon as it is remembered. If it is close to the time for the next scheduled dose, official guidance is to skip the missed dose and resume the regular schedule. It is also noted that double doses should not be taken.


Q: What does Urose actually treat, besides the main condition?

A: In addition to its primary uses for Primary Biliary Cholangitis (PBC) and gallstone dissolution, Urose (ursodiol) has been studied and designated as an orphan drug for the treatment of certain hepatobiliary disorders associated with Cystic Fibrosis.


Q: Is Urose safe for elderly patients to use?

A: Official regulatory documents state that no specific dosage adjustment is generally required for older adults. This indicates that its use is addressed in the standard prescribing information.


Q: Does Urose cause drowsiness or affect ability to drive?

A: Headache and dizziness are commonly reported side effects in the official clinical data. Official information notes that if side effects such as dizziness occur, it may affect the ability to drive or operate machinery.


Q: Can Urose be used by people with a history of kidney stones?

A: Regulatory labeling lists complete biliary obstruction and calcified gallstones as contraindications. Official regulatory labeling for Urose does not list a history of kidney stones as a contraindication.


Q: Why do some people say Urose makes their urine a different color?

A: While the drug itself may not directly change urine color, official adverse reaction reports note that dark urine can be a potential sign of serious liver issues, which should be reported to a healthcare provider.


Q: Is Urose available over-the-counter or is it prescription only?

A: According to the official drug class and label information, Urose (Ursodiol) is classified as a prescription-only pharmaceutical preparation and is not available over-the-counter.


Q: Is there a generic version of Urose available?

A: Yes, the active ingredient, Ursodiol (Ursodeoxycholic Acid), is widely available in generic formulations, which are listed in official regulatory databases.


Q: What are the signs that Urose is actually working for me?

A: In clinical trials, the effectiveness of Urose was primarily determined by measured changes in liver biochemical markers. These include laboratory values such as alkaline phosphatase (ALP) and total bilirubin levels.


Q: Has Urose been studied in children?

A: Studies have been conducted on its use in children under restricted conditions. While safety and efficacy are not established for all pediatric uses, it may be used for hepatobiliary disorders associated with Cystic Fibrosis.


Q: Are there specific times of day that are best for taking Urose?

A: Official dosing guidelines state that the total daily dose is typically administered in divided portions. The largest portion, or the entire dose, is often recommended to be administered at bedtime to optimize bile saturation.


Q: Do people with diabetes need to be careful when using Urose?

A: Official adverse reaction reports list elevated blood glucose levels as a possible side effect, suggesting that individuals with diabetes should be aware of this potential effect.


Q: Is it possible for Urose to stop working after a while?

A: Clinical research notes the existence of patients classified as 'biochemical non-responders,' which indicates that a diminished response to the treatment can occur over time.


Q: What is the difference between Urose and a standard painkiller?

A: Urose is classified as a Cholelitholytic agent and Hepatoprotective agent, meaning it works on bile and liver health. A standard painkiller, or analgesic, belongs to a completely different pharmacological class, as its primary function is to relieve pain.


Q: Is Urose a steroid?

A: Chemically, the active ingredient in Urose, Ursodeoxycholic Acid, is classified as a bile acid. Bile acids are organic compounds that belong to the larger chemical group known as C24 -steroids.


Q: How is Urose different from a prophylactic medication?

A: While Urose is often used to treat existing conditions like Primary Biliary Cholangitis, it is also officially indicated for prophylactic use, such as preventing gallstone formation during periods of rapid weight loss.


Q: What happens if I take Urose with a high-fat meal?

A: While the specific effects of a very high-fat meal are not detailed in the official prescribing information, it is generally recommended that the medication be taken with food or meals, as this is known to improve absorption.

How should Urose be stored and disposed of?

Urose (Ursodiol) must be stored under specific regulatory conditions to ensure its stability and effectiveness, and disposal must follow official guidelines.

Required Storage Conditions

Urose must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The container must be kept tightly closed to protect the contents from excess heat and moisture. It is a mandatory requirement to keep from freezing and to store the medication out of the reach and sight of children.

Official Disposal Instructions

Disposal of unused or expired Urose should utilize an authorized drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an unappealing substance (such as dirt or coffee grounds) and placed into a sealed container before being discarded in the household trash. Tablets or capsules must not be crushed during this process.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Urose found in:

A-Z Index: